Skip to content

Hikma Appoints Former Cipla CEO Vohra

Hikma Pharmaceuticals has named Umang Vohra, the former Cipla chief executive, as an independent non-executive director from the 1st of December, with seats on its Audit and Nomination and Governance Committees.

Hikma Pharmaceuticals has appointed Umang Vohra as an independent non-executive director, effective the 1st of December. The company announced the appointment today.

From the same date Vohra will also join two board committees: the Audit Committee and the Nomination and Governance Committee.

Hikma is headquartered in the UK and has more than 45 years of history, 9,500 colleagues and operations across North America, the Middle East and North Africa (MENA) and Europe. It is rated BBB with a stable outlook by both S&P and Fitch.

The appointment is a board change rather than a trading update. Hikma is listed in London (LSE: HIK) and on NASDAQ Dubai (HIK), and trades over the counter in the US (OTC: HKMPY).

HIK.LSE

Victoria Hull, Hikma’s chair, said:

I am delighted to welcome Umang to the Hikma Board. Umang is an experienced CEO with deep knowledge of the generic pharmaceutical market and an impressive track record in growth, innovation, portfolio development and transformation. His extensive international experience, particularly in North America, will bring valuable perspective to the Board.

Victoria Hull, Chair, Hikma

Vohra is currently chair and chief executive of Cohance Lifesciences Limited, an end-to-end, innovation-led contract development and manufacturing organisation (CDMO) listed in India. He divides his time between the US and India.

He is also an independent board member of AGS Health, a revenue cycle management company registered in India.

Vohra was previously chief executive of Cipla Limited, where he is credited with transforming the business into a diversified global pharmaceutical enterprise. Earlier he held senior roles at Dr. Reddy’s Laboratories Limited, including chief financial officer and head of its North American business.

Hikma made the announcement under Listing Rule 6.4.6 and said no further information needs to be disclosed under Listing Rule 6.4.8.

Asktraders News Team
Asktraders News Team
Team Member

The AskTraders Analyst Team features experts in technical and fundamental analysis, as well as traders specializing in stocks, forex, and cryptocurrency.

Stay ahead of the markets

Sign up to our free Morning Markets email, every weekday before the open.